Prosight Management’s Lipocine LPCN Stock Holding History

Prosight Management’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-21,947	Closed	-$1.28M	–	34
2017 Q4	$1.28M	Buy	+21,947	New	+$1.36M	0.94%	25

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Prosight Management's LPCN Position: Q1 2018 in Review

Prosight Management sold out of Lipocine (LPCN) in Q1 2018, closing a stake of 21,947 shares — an estimated $1.28M sold.

Prosight Management first reported a position in LPCN in Q4 2017 and held it in 1 quarter. The position peaked at $1.28M in Q4 2017. 27 funds tracked by Wall St. Rank hold LPCN as of Q1 2018.

Prosight Management reported no remaining Lipocine position as of Q1 2018 after selling out during the quarter.
Prosight Management sold 21,947 Lipocine shares in Q1 2018, an estimated $1.28M.
Prosight Management first reported a position in Lipocine in Q4 2017 and held it in 1 quarter.
Prosight Management's Lipocine position peaked at $1.28M in Q4 2017.
27 funds tracked by Wall St. Rank held Lipocine as of Q1 2018.

Based on Prosight Management's 13F filing for Q1 2018, filed 14 May 2018.